Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy

Hongmei Ruan1, Scherise Mitchell, Monika Vainoriene

  • 1Department of Anesthesiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.

Circulation
|July 25, 2007
PubMed

Insights

Cardiac hypertrophy leads to arrhythmias via signaling pathways. Inhibiting G alpha inhibiting subunit 1 (Gi alpha1) reversed electrical remodeling and reduced arrhythmias in a mouse model.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cardiac Electrophysiology

Background:

  • Cardiac hypertrophy is a significant risk factor for potentially fatal arrhythmias.
  • The precise signaling mechanisms driving arrhythmia induction and electrophysiological remodeling in cardiac hypertrophy remain incompletely understood.

Purpose of the Study:

  • To investigate the signaling pathways involved in cardiac hypertrophy and associated arrhythmias.
  • To elucidate the role of specific signaling molecules in the electrophysiological remodeling of hypertrophic hearts.

Main Methods:

  • Utilized an inducible gene-switch system for temporal and tissue-specific activation of the Ras-Raf-mitogen-activated protein kinases pathway in adult mouse hearts.
  • Analyzed electrophysiological properties of isolated ventricular myocytes.
  • Performed genome-wide expression profiling to identify differentially expressed genes.

Main Results:

  • Ras activation induced ventricular hypertrophy and arrhythmias, temporally correlated with electrophysiological remodeling.
  • Observed action potential prolongation, altered ion channel activity, sarcoplasmic reticulum Ca2+ defects, and reduced protein kinase A-dependent phospholamban phosphorylation.
  • Discovered selective induction of G alpha inhibiting subunit 1 (Gi alpha1) expression in hypertrophic hearts.

Conclusions:

  • Selective induction of Gi alpha1 is a novel downstream event in hypertrophic signaling.
  • Gi alpha1 activity appears critical for cellular electrophysiological remodeling and arrhythmia development in hypertrophic cardiomyopathy.
  • Pertussis toxin treatment, inhibiting Gi/o proteins, normalized key electrophysiological parameters and reduced arrhythmia frequency.
Abstract

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753